+44 20 8123 2220
info@marketpublishers.com

2020 Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

https://marketpublishers.com/r/20ACBED1BC2DEN.html
Date: February 2020
Pages: 155
Price: US$ 1,999.00 (Single User License)
ID: 20ACBED1BC2DEN

Abstracts

The 2020 Attention Deficit Hyperactivity Disorder (ADHD) pipeline report presents a comprehensive overview of the research and development of Attention Deficit Hyperactivity Disorder (ADHD) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in Research phase, 11 drugs in Pre-clinical phase, ten drugs in Phase 1, nine drugs in Phase 2, six drugs in Phase 3 and two drugs in Preregistration

As of February 2020, the Attention Deficit Hyperactivity Disorder (ADHD) pipeline remains robust with 43 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Attention Deficit Hyperactivity Disorder (ADHD) treatment. Diverse types of targeted therapies are being explored through clinical trials including Adrenergic receptor agonists; adrenergic reuptake inhibitor; Adrenergic uptake inhibitors; Alpha 2 adrenergic receptor agonists; AMPA receptor modulators; Central nervous system stimulants; Dopamine D2 receptor antagonists; Dopamine D2/D3/D4 receptor partial agonists; Dopamine release stimulants; dopamine reuptake inhibitor; dopamine transporter inhibitor; Dopamine uptake inhibitors; histamine agonist; noradrenaline transporter inhibitor; norepinephrine reuptake inhibitor; Opioid mu receptor antagonists; Serotonin 1A/2A receptor agonists; Serotonin 1B receptor agonists; Serotonin 6 receptor antagonists; Serotonin 7 receptor antagonists; serotonin reuptake inhibitor; serotonin transporter inhibitor.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type,

and other details. Further, the report also provides Attention Deficit Hyperactivity Disorder (ADHD) drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

PUBLISHER EXPERTISE

VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

SCOPE:

The report scope comprises of both pre-clinical phase and clinical phase development drugs for Attention Deficit Hyperactivity Disorder (ADHD) development

Attention Deficit Hyperactivity Disorder (ADHD) pipeline compounds and molecules under study by both large scale and small companies are included in the report

Attention Deficit Hyperactivity Disorder (ADHD) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered

Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered

Further, orphan drug status, fast track designation, different grants awarded and special status for Attention Deficit Hyperactivity Disorder (ADHD) pipeline candidates included

Business overview and snapshot of all companies involved in Attention Deficit Hyperactivity Disorder (ADHD) pipeline are included

Latest market and pipeline developments are provided in the report

Attention Deficit Hyperactivity Disorder (ADHD) pipeline companies included in the report are- 4P-Pharma SAS, Altus Formulation Inc, Amarantus Bioscience Holdings Inc, APeT Holding BV, Arbor Pharmaceuticals LLC, Attentive Therapeutics Inc , Avekshan LLC, BCWorld Pharm Co Ltd, BioHealthonomics Inc, Cennerv Pharma (S) Pte Ltd, Cerecor Inc, Cingulate Therapeutics LLC, Collegium Pharmaceutical Inc, Curemark LLC, DURECT Corp, Eli Lilly and Co, EncepHeal Therapeutics Inc, Ensysce Biosciences Inc, Highland Therapeutics Inc, KemPharm Inc, Limoxifen BV, NLS Pharma Group, Noven Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Otsuka Pharmaceutical Co Ltd, P2D Inc, RespireRx Pharmaceuticals Inc, Reviva Pharmaceuticals Inc, Shenox Pharmaceuticals LLC, SK Biopharmaceuticals Co Ltd, Sunovion Pharmaceuticals Inc, Supernus Pharmaceuticals Inc, Taho Pharmaceuticals Ltd, Terran Biosciences Inc , Tris Pharma Inc, Vallon Pharmaceuticals Inc

Attention Deficit Hyperactivity Disorder (ADHD) pipeline drugs profiled in the report include- 4P-003, AFI-002, eltoprazine, niacinamide CR, Amphetamine sulfate, ATT-377, AVK-001 (methylphenidate and naltrexone), BCWP-E003, histamine dihydrochloride, CB8411, CERC-701, CERC-702, dexmethylphenidate hydrochloride, COL-171 (methylphenidate extended-release), CM-4612, methylphenidate sustained release, edivoxetine hydrochloride, ECH-201, PF8001, PF8026, HLD100 (dextroamphetamine modified release), KP484, KP415 (serdexmethylphenidate chloride), guanfacine, NLS-3 (Phacetoperane), NLS-4 (Lauflumide), NLS-8, mazindol controlled release, dextroamphetamine, OPC-64005, EB-1020 (centanafadine SR), PD-3044, CX717, brilaroxazine, SHX-009, SKL13865, dasotraline, SPN-810 (molindone hydrochloride), SPN-812 (viloxazine hydrochloride), TAH9922 (atomoxetine hydrochloride), Drugs for ADHD and Migraine, TRN-110, dextroamphetamine immediate release

+44 20 8123 2220
info@marketpublishers.com

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. EXECUTIVE SUMMARY

2.1 Report Scope and Research Methodology
2.2 Introduction to Attention Deficit Hyperactivity Disorder (ADHD) Condition
2.3 Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Snapshot, 2020
2.4 Companies investing in Attention Deficit Hyperactivity Disorder (ADHD) pipeline therapeutics
2.5 Phase wise Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Products
2.7 Route of Administration of Attention Deficit Hyperactivity Disorder (ADHD) Pipeline Drugs

3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT

3.1 4P-Pharma SAS Overview, Contacts and ASD Pipeline Drugs
3.2 Altus Formulation Inc Overview, Contacts and ASD Pipeline Drugs
3.3 Amarantus Bioscience Holdings Inc Overview, Contacts and ASD Pipeline Drugs
3.4 APeT Holding BV Overview, Contacts and ASD Pipeline Drugs
3.5 Arbor Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
3.6 Attentive Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Avekshan LLC Overview, Contacts and ASD Pipeline Drugs
3.8 BCWorld Pharm Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.9 BioHealthonomics Inc Overview, Contacts and ASD Pipeline Drugs
3.10 Cennerv Pharma (S) Pte Ltd Overview, Contacts and ASD Pipeline Drugs
3.11 Cerecor Inc Overview, Contacts and ASD Pipeline Drugs
3.12 Cingulate Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
3.13 Collegium Pharmaceutical Inc Overview, Contacts and ASD Pipeline Drugs
3.14 Curemark LLC Overview, Contacts and ASD Pipeline Drugs
3.15 DURECT Corp Overview, Contacts and ASD Pipeline Drugs
3.16 Eli Lilly and Co Overview, Contacts and ASD Pipeline Drugs
3.17 EncepHeal Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs

3.18 Ensysce Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.19 Highland Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.20 KemPharm Inc Overview, Contacts and ASD Pipeline Drugs
3.21 Limoxifen BV Overview, Contacts and ASD Pipeline Drugs
3.22 NLS Pharma Group Overview, Contacts and ASD Pipeline Drugs
3.23 Noven Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.24 Otsuka Holdings Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.25 Otsuka Pharmaceutical Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.26 P2D Inc Overview, Contacts and ASD Pipeline Drugs
3.27 RespireRx Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.28 Reviva Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.29 Shenox Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
3.30 SK Biopharmaceuticals Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.31 Sunovion Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.32 Supernus Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.33 Taho Pharmaceuticals Ltd Overview, Contacts and ASD Pipeline Drugs
3.34 Terran Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.35 Tris Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.36 Vallon Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs

4. ACTIVE PIPELINE DRUG DETAILS, 2020

4.1 4P-003 Drug Details
  4.1.1 4P-003 Current Status
  4.1.2 4P-003 Drug Overview
  4.1.3 4P-003 Mechanism of Action
  4.1.4 4P-003 Licensing/Collaboration Companies
  4.1.5 4P-003 Clinical Trials
4.2 AFI-002 Drug Details
  4.2.1 AFI-002 Current Status
  4.2.2 AFI-002 Drug Overview
  4.2.3 AFI-002 Mechanism of Action
  4.2.4 AFI-002 Licensing/Collaboration Companies
  4.2.5 AFI-002 Clinical Trials
4.3 eltoprazine Drug Details
  4.3.1 eltoprazine Current Status
  4.3.2 eltoprazine Drug Overview
  4.3.3 eltoprazine Mechanism of Action
  4.3.4 eltoprazine Licensing/Collaboration Companies

4.3.5 eltoprazine Clinical Trials
4.4 niacinamide CR Drug Details
4.4.1 niacinamide CR Current Status
4.4.2 niacinamide CR Drug Overview
4.4.3 niacinamide CR Mechanism of Action
4.4.4 niacinamide CR Licensing/Collaboration Companies
4.4.5 niacinamide CR Clinical Trials
4.5 Amphetamine sulfate Drug Details
4.5.1 Amphetamine sulfate Current Status
4.5.2 Amphetamine sulfate Drug Overview
4.5.3 Amphetamine sulfate Mechanism of Action
4.5.4 Amphetamine sulfate Licensing/Collaboration Companies
4.5.5 Amphetamine sulfate Clinical Trials
4.6 ATT-377 Drug Details
4.6.1 ATT-377 Current Status
4.6.2 ATT-377 Drug Overview
4.6.3 ATT-377 Mechanism of Action
4.6.4 ATT-377 Licensing/Collaboration Companies
4.6.5 ATT-377 Clinical Trials
4.7 AVK-001 (methylphenidate and naltrexone) Drug Details
4.7.1 AVK-001 (methylphenidate and naltrexone) Current Status
4.7.2 AVK-001 (methylphenidate and naltrexone) Drug Overview
4.7.3 AVK-001 (methylphenidate and naltrexone) Mechanism of Action
4.7.4 AVK-001 (methylphenidate and naltrexone) Licensing/Collaboration Companies
4.7.5 AVK-001 (methylphenidate and naltrexone) Clinical Trials
4.8 BCWP-E003 Drug Details
4.8.1 BCWP-E003 Current Status
4.8.2 BCWP-E003 Drug Overview
4.8.3 BCWP-E003 Mechanism of Action
4.8.4 BCWP-E003 Licensing/Collaboration Companies
4.8.5 BCWP-E003 Clinical Trials
4.9 histamine dihydrochloride Drug Details
4.9.1 histamine dihydrochloride Current Status
4.9.2 histamine dihydrochloride Drug Overview
4.9.3 histamine dihydrochloride Mechanism of Action
4.9.4 histamine dihydrochloride Licensing/Collaboration Companies
4.9.5 histamine dihydrochloride Clinical Trials
4.10 CB8411 Drug Details
4.10.1 CB8411 Current Status

4.10.2 CB8411 Drug Overview
4.10.3 CB8411 Mechanism of Action
4.10.4 CB8411 Licensing/Collaboration Companies
4.10.5 CB8411 Clinical Trials
4.11 CERC-701 Drug Details
4.11.1 CERC-701 Current Status
4.11.2 CERC-701 Drug Overview
4.11.3 CERC-701 Mechanism of Action
4.11.4 CERC-701 Licensing/Collaboration Companies
4.11.5 CERC-701 Clinical Trials
4.12 CERC-702 Drug Details
4.12.1 CERC-702 Current Status
4.12.2 CERC-702 Drug Overview
4.12.3 CERC-702 Mechanism of Action
4.12.4 CERC-702 Licensing/Collaboration Companies
4.12.5 CERC-702 Clinical Trials
4.13 dexmethylphenidate hydrochloride Drug Details
4.13.1 dexmethylphenidate hydrochloride Current Status
4.13.2 dexmethylphenidate hydrochloride Drug Overview
4.13.3 dexmethylphenidate hydrochloride Mechanism of Action
4.13.4 dexmethylphenidate hydrochloride Licensing/Collaboration Companies
4.13.5 dexmethylphenidate hydrochloride Clinical Trials
4.14 COL-171 (methylphenidate extended-release) Drug Details
4.14.1 COL-171 (methylphenidate extended-release) Current Status
4.14.2 COL-171 (methylphenidate extended-release) Drug Overview
4.14.3 COL-171 (methylphenidate extended-release) Mechanism of Action
4.14.4 COL-171 (methylphenidate extended-release) Licensing/Collaboration Companies
4.14.5 COL-171 (methylphenidate extended-release) Clinical Trials
4.15 CM-4612 Drug Details
4.15.1 CM-4612 Current Status
4.15.2 CM-4612 Drug Overview
4.15.3 CM-4612 Mechanism of Action
4.15.4 CM-4612 Licensing/Collaboration Companies
4.15.5 CM-4612 Clinical Trials
4.16 methylphenidate sustained release Drug Details
4.16.1 methylphenidate sustained release Current Status
4.16.2 methylphenidate sustained release Drug Overview
4.16.3 methylphenidate sustained release Mechanism of Action

4.16.4 methylphenidate sustained release Licensing/Collaboration Companies
4.16.5 methylphenidate sustained release Clinical Trials
4.17 edivoxetine hydrochloride Drug Details
4.17.1 edivoxetine hydrochloride Current Status
4.17.2 edivoxetine hydrochloride Drug Overview
4.17.3 edivoxetine hydrochloride Mechanism of Action
4.17.4 edivoxetine hydrochloride Licensing/Collaboration Companies
4.17.5 edivoxetine hydrochloride Clinical Trials
4.18 ECH-201 Drug Details
4.18.1 ECH-201 Current Status
4.18.2 ECH-201 Drug Overview
4.18.3 ECH-201 Mechanism of Action
4.18.4 ECH-201 Licensing/Collaboration Companies
4.18.5 ECH-201 Clinical Trials
4.19 PF8001 Drug Details
4.19.1 PF8001 Current Status
4.19.2 PF8001 Drug Overview
4.19.3 PF8001 Mechanism of Action
4.19.4 PF8001 Licensing/Collaboration Companies
4.19.5 PF8001 Clinical Trials
4.20 PF8026 Drug Details
4.20.1 PF8026 Current Status
4.20.2 PF8026 Drug Overview
4.20.3 PF8026 Mechanism of Action
4.20.4 PF8026 Licensing/Collaboration Companies
4.20.5 PF8026 Clinical Trials
4.21 HLD100 (dextroamphetamine modified release) Drug Details
4.21.1 HLD100 (dextroamphetamine modified release) Current Status
4.21.2 HLD100 (dextroamphetamine modified release) Drug Overview
4.21.3 HLD100 (dextroamphetamine modified release) Mechanism of Action
4.21.4 HLD100 (dextroamphetamine modified release) Licensing/Collaboration Companies
4.21.5 HLD100 (dextroamphetamine modified release) Clinical Trials
4.22 KP484 Drug Details
4.22.1 KP484 Current Status
4.22.2 KP484 Drug Overview
4.22.3 KP484 Mechanism of Action
4.22.4 KP484 Licensing/Collaboration Companies
4.22.5 KP484 Clinical Trials

4.23 KP415 (serdexmethylphenidate chloride) Drug Details
4.23.1 KP415 (serdexmethylphenidate chloride) Current Status
4.23.2 KP415 (serdexmethylphenidate chloride) Drug Overview
4.23.3 KP415 (serdexmethylphenidate chloride) Mechanism of Action
4.23.4 KP415 (serdexmethylphenidate chloride) Licensing/Collaboration Companies
4.23.5 KP415 (serdexmethylphenidate chloride) Clinical Trials
4.24 guanfacine Drug Details
4.24.1 guanfacine Current Status
4.24.2 guanfacine Drug Overview
4.24.3 guanfacine Mechanism of Action
4.24.4 guanfacine Licensing/Collaboration Companies
4.24.5 guanfacine Clinical Trials
4.25 NLS-3 (Phacetoperane) Drug Details
4.25.1 NLS-3 (Phacetoperane) Current Status
4.25.2 NLS-3 (Phacetoperane) Drug Overview
4.25.3 NLS-3 (Phacetoperane) Mechanism of Action
4.25.4 NLS-3 (Phacetoperane) Licensing/Collaboration Companies
4.25.5 NLS-3 (Phacetoperane) Clinical Trials
4.26 NLS-4 (Lauflumide) Drug Details
4.26.1 NLS-4 (Lauflumide) Current Status
4.26.2 NLS-4 (Lauflumide) Drug Overview
4.26.3 NLS-4 (Lauflumide) Mechanism of Action
4.26.4 NLS-4 (Lauflumide) Licensing/Collaboration Companies
4.26.5 NLS-4 (Lauflumide) Clinical Trials
4.27 NLS-8 Drug Details
4.27.1 NLS-8 Current Status
4.27.2 NLS-8 Drug Overview
4.27.3 NLS-8 Mechanism of Action
4.27.4 NLS-8 Licensing/Collaboration Companies
4.27.5 NLS-8 Clinical Trials
4.28 mazindol controlled release Drug Details
4.28.1 mazindol controlled release Current Status
4.28.2 mazindol controlled release Drug Overview
4.28.3 mazindol controlled release Mechanism of Action
4.28.4 mazindol controlled release Licensing/Collaboration Companies
4.28.5 mazindol controlled release Clinical Trials
4.29 dextroamphetamine Drug Details
4.29.1 dextroamphetamine Current Status
4.29.2 dextroamphetamine Drug Overview

4.29.3 dextroamphetamine Mechanism of Action
4.29.4 dextroamphetamine Licensing/Collaboration Companies
4.29.5 dextroamphetamine Clinical Trials
4.30 OPC-64005 Drug Details
4.30.1 OPC-64005 Current Status
4.30.2 OPC-64005 Drug Overview
4.30.3 OPC-64005 Mechanism of Action
4.30.4 OPC-64005 Licensing/Collaboration Companies
4.30.5 OPC-64005 Clinical Trials
4.31 EB-1020 (centanafadine SR) Drug Details
4.31.1 EB-1020 (centanafadine SR) Current Status
4.31.2 EB-1020 (centanafadine SR) Drug Overview
4.31.3 EB-1020 (centanafadine SR) Mechanism of Action
4.31.4 EB-1020 (centanafadine SR) Licensing/Collaboration Companies
4.31.5 EB-1020 (centanafadine SR) Clinical Trials
4.32 PD-3044 Drug Details
4.32.1 PD-3044 Current Status
4.32.2 PD-3044 Drug Overview
4.32.3 PD-3044 Mechanism of Action
4.32.4 PD-3044 Licensing/Collaboration Companies
4.32.5 PD-3044 Clinical Trials
4.33 CX717 Drug Details
4.33.1 CX717 Current Status
4.33.2 CX717 Drug Overview
4.33.3 CX717 Mechanism of Action
4.33.4 CX717 Licensing/Collaboration Companies
4.33.5 CX717 Clinical Trials
4.34 brilaroxazine Drug Details
4.34.1 brilaroxazine Current Status
4.34.2 brilaroxazine Drug Overview
4.34.3 brilaroxazine Mechanism of Action
4.34.4 brilaroxazine Licensing/Collaboration Companies
4.34.5 brilaroxazine Clinical Trials
4.35 SHX-009 Drug Details
4.35.1 SHX-009 Current Status
4.35.2 SHX-009 Drug Overview
4.35.3 SHX-009 Mechanism of Action
4.35.4 SHX-009 Licensing/Collaboration Companies
4.35.5 SHX-009 Clinical Trials

4.36 SKL13865 Drug Details
4.36.1 SKL13865 Current Status
4.36.2 SKL13865 Drug Overview
4.36.3 SKL13865 Mechanism of Action
4.36.4 SKL13865 Licensing/Collaboration Companies
4.36.5 SKL13865 Clinical Trials
4.37 dasotraline Drug Details
4.37.1 dasotraline Current Status
4.37.2 dasotraline Drug Overview
4.37.3 dasotraline Mechanism of Action
4.37.4 dasotraline Licensing/Collaboration Companies
4.37.5 dasotraline Clinical Trials
4.38 SPN-810 (molindone hydrochloride) Drug Details
4.38.1 SPN-810 (molindone hydrochloride) Current Status
4.38.2 SPN-810 (molindone hydrochloride) Drug Overview
4.38.3 SPN-810 (molindone hydrochloride) Mechanism of Action
4.38.4 SPN-810 (molindone hydrochloride) Licensing/Collaboration Companies
4.38.5 SPN-810 (molindone hydrochloride) Clinical Trials
4.39 SPN-812 (viloxazine hydrochloride) Drug Details
4.39.1 SPN-812 (viloxazine hydrochloride) Current Status
4.39.2 SPN-812 (viloxazine hydrochloride) Drug Overview
4.39.3 SPN-812 (viloxazine hydrochloride) Mechanism of Action
4.39.4 SPN-812 (viloxazine hydrochloride) Licensing/Collaboration Companies
4.39.5 SPN-812 (viloxazine hydrochloride) Clinical Trials
4.40 TAH9922 (atomoxetine hydrochloride) Drug Details
4.40.1 TAH9922 (atomoxetine hydrochloride) Current Status
4.40.2 TAH9922 (atomoxetine hydrochloride) Drug Overview
4.40.3 TAH9922 (atomoxetine hydrochloride) Mechanism of Action
4.40.4 TAH9922 (atomoxetine hydrochloride) Licensing/Collaboration Companies
4.40.5 TAH9922 (atomoxetine hydrochloride) Clinical Trials
4.41 Drugs for ADHD and Migraine Drug Details
4.41.1 Drugs for ADHD and Migraine Current Status
4.41.2 Drugs for ADHD and Migraine Drug Overview
4.41.3 Drugs for ADHD and Migraine Mechanism of Action
4.41.4 Drugs for ADHD and Migraine Licensing/Collaboration Companies
4.41.5 Drugs for ADHD and Migraine Clinical Trials
4.42 TRN-110 Drug Details
4.42.1 TRN-110 Current Status
4.42.2 TRN-110 Drug Overview

4.42.3 TRN-110 Mechanism of Action
4.42.4 TRN-110 Licensing/Collaboration Companies
4.42.5 TRN-110 Clinical Trials
4.43 dextroamphetamine immediate release Drug Details
4.43.1 dextroamphetamine immediate release Current Status
4.43.2 dextroamphetamine immediate release Drug Overview
4.43.3 dextroamphetamine immediate release Mechanism of Action
4.43.4 dextroamphetamine immediate release Licensing/Collaboration Companies
4.43.5 dextroamphetamine immediate release Clinical Trials

5. LATEST ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE NEWS AND DEALS

6. APPENDIX

6.1 Our Databases and Reports
6.2 Research Methodolgy

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: 2020 Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

Product link: https://marketpublishers.com/r/20ACBED1BC2DEN.html

Price: US$ 1,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/20ACBED1BC2DEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below

+44 20 8123 2220
info@marketpublishers.com

and fax the completed form to +44 20 7900 3970